AbiVax Poised For 'Transformational' Q2

Key Clinical Readouts Set To Spur Partnering Talks

 
• By Sten Stovall
  
UC
AbiVax’s anti-inflammatory ABX464 Central Focus • Source: Shutterstock

More from Clinical Trials

More from R&D